Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
Q4 2024 Management View CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, ...